Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. Cyagen currently has over 900 employees and multiple facilities with a total scale of over 40,000 square meters, including our US headquarters in Santa Clara, California, and additional locations in Japan and China. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.
One-Stop Solutions for All Research Model Needs
Our comprehensive services cover the entire process of model generation: from transgenic/gene targeting strategy design, through model development, breeding, cryopreservation, and phenotype analysis. Our CRO service platforms provide everything required for drug discovery and preclinical research, including specialty cell and gene therapy (CGT) therapeutic areas, such as ophthalmology, immuno-oncology, and neuroscience.
Innovative "AI+CGT"service platform
Combining wet-lab experiments, bioinformatics and AI, our team has collected a large amount of data and built many proprietary AI models for cell and gene (CGT) therapy research, providing a range of preclinical services including: prediction of human gene mutation pathogenicity, design of mouse disease models, and accelerate the discovery of novel CGT drugs, such as adeno-associated virus (AAV) vectors and CAR-T cell therapies.
For example, utilizing AI and single-cell RNA-sequencing technologies, Cyagen's high-throughput AAV vector discovery platform helps overcome the present limitations of gene therapy R&D by quickly identifying next-generation AAV capsids that have enhanced tissue targeting capability, tissue specificity, and productivity. Cyagen has produced substantial experimental data for AI model training and developed proprietary machine learning algorithms to accelerate the AAV capsid identification and optimization processes compared to traditional directed evolution methods.
At the same time, Cyagen also provides full support for cell therapy R&D. Cyagen’s fully-humanized antibody screening platform allows discoveries of novel antibody drugs and CAR-T cell therapy drugs. Combined with our virus packaging, mouse model construction and pharmacodynamic CRO capabilities, we provide one-stop solutions for all stages of preclinical cell therapy R&D.
Cyagen Knockout Catalog Models: Extensive KO/cKO Mouse Strain Library Resource
The Cyagen Knockout Catalog Models repository provides a searchable listing of over 16k mouse strains in more than 20 research fields, including oncology, cardiology, and neurology. You can quickly query the required genetically engineered global knockout (KO) mouse, conditional knockout (cKO/floxed) mouse and microRNA KO mouse strains by simply entering the gene name. The powerful database offers you a more convenient experience by streamlining the process of identifying KO mouse models and ordering them for research.
Cyagen subdivides different mouse models into applied research fields and provides detailed information about the backgrounds and associated applications of the models to help simplify the model selection process.
Expertly customized mouse models
Cyagen has 16 years of experience in the field of model animal customization and has developed a number of technological innovations. Cyagen can develop any desired mouse models for customers through CRISPR gene editing, TurboKnockout gene editing, transgenic and other technologies. Cyagen’s innovative genetic modification techniques allow easier, faster and more efficient knock-in (KI), KO and other gene editing capabilities during mouse model generation without the concerns of off-target effects or patent disputes.
One-stop in vivo and in vitro drug efficacy evaluation platform
Cyagen has established a one-stop CRO platform for drug development, screening, and drug efficacy evaluation covering a wide range of research areas, including oncology, immunology, metabolism, cardiology, neurology, ophthalmology, and infectious diseases. Cyagen’s one-stop in vivo and in vitro drug efficacy service platform can provide services including immunological testing, physiological and biochemical testing, behavioral testing, cell function testing, molecular biology testing, in vivo imaging, pathology and other specific disease phenotype analyses.
Animal disease models are an indispensable tool to study the mechanisms of human disease development, and can be used for drug screening and efficacy evaluations. Choosing the right disease animal models can accelerate the development of new drugs. To provide the highest-quality models to researchers, we continuously optimize our gene editing technologies and recruit seasoned specialists to support our scientific innovation together.
Rare Disease Data Center (RDDC): AI-enabled bioinformatics research tools
Publicly launched in February 2022, the Rare Disease Data Center (RDDC) has been developed by the artificial intelligence innovation center of Tsinghua Pearl River Delta Research Institute and Cyagen as part of their participation in the Rare Disease Gene Therapy Alliance, providing support for improved dissemination of biological and genetics information and knowledge. The RDDC focuses on providing comprehensive genetic data visualization & AI-powered pathogenic analysis tools for rare disease research. It integrates all reported rare disease data and gene information, including: epidemiological data, disease-related gene profile, variants, phenotypes, drug developmental outlines, and disease-associated mouse models. The purpose of RDDC is to help doctors, researchers, pharmaceutical companies, as well as patients and their families, to quickly analyze and understand any rare disease. It also integrates China’s domestic rare disease-related data resources to provide a comprehensive data profile for scientific and clinical research of rare diseases.
